Netarsudil

Skye Bioscience Announces $50.25 Million Private Placement Equity Financing

Retrieved on: 
Monday, January 29, 2024
Obesity, OE, Patient, PIPE, Richard Driehaus, Leptin, Fasting, Visium Asset Management, Sale, Ocular hypertension, OTCQB, Exchange, CB1, Safety, Triglyceride, Netarsudil, Glaucoma, Waist, Cholesterol, Security (finance), Body composition, Oppenheimer Holdings, Pharmaceutical industry

Financing co-led by a leading life science investor and 5AM Ventures expected to fully fund obesity Phase 2 trial assessing nimacimab, Skye's differentiated peripheral CB1 inhibitor, in combination with a GLP-1R agonist

Key Points: 
  • Gross proceeds from the PIPE are expected to be $50.25 million, before deducting any placement agent fees and offering-related expenses.
  • The PIPE financing is expected to close on January 31, 2024, subject to the satisfaction of customary closing conditions.
  • The PIPE financing was co-led by a life sciences-focused investor and 5AM Ventures, with participation from Ally Bridge Group, Sphera Healthcare, Altium Capital, Driehaus Capital Management and other institutional investors.
  • Piper Sandler is acting as the lead placement agent and Oppenheimer & Co. is acting as a placement agent for the PIPE financing.

Aerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emerging Treatment Options

Retrieved on: 
Tuesday, September 13, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Optical, Ocular hypertension, Aerie, IOP, Molecular biology, FDA, MD, Food, Glaucoma, Ophthalmology, Netarsudil, TRPM8, Aerie Pharmaceuticals, Creativity, Diabetic retinopathy, Emerging, Medicine, Review, Private Securities Litigation Reform Act, Phase 3, DME, Industry, DED, Forward-looking statement, U.S. Securities and Exchange Commission, Cornea, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, 2021 Essex County Council election, Amgen, Solution, Medication, Science, Duane syndrome, NASDAQ, Conjunctivitis, Eye, Board, Security (finance), SEC, Population and Community Development Association, KOL, Disease, Pharmaceutical industry

The event will feature Dr. Laura Periman, MD, of the Periman Eye Institute, and Dr. John Sheppard, MD, of the Virginia Eye Consultants, who will discuss New Perspectives on Dry Eye Disease (DED), including the Current Landscape, Unmet Medical Needs, and Emerging Treatment Options, including Aeries investigational TRPM8 agonist, AR-15512.

Key Points: 
  • The event will feature Dr. Laura Periman, MD, of the Periman Eye Institute, and Dr. John Sheppard, MD, of the Virginia Eye Consultants, who will discuss New Perspectives on Dry Eye Disease (DED), including the Current Landscape, Unmet Medical Needs, and Emerging Treatment Options, including Aeries investigational TRPM8 agonist, AR-15512.
  • Dr. Periman is a Cornea and Refractive Surgery Fellowship trained physician and surgeon with roots as a molecular biologist.
  • Dr. Periman is a dry eye expert who has spent years in private practices focusing on the disease, before opening and running the Periman Eye Institute.
  • He is committed to providing the highest quality eye care solutions and is widely regarded as a leader in his field.

Aerie Pharmaceuticals Announces New Employee Inducement Grant

Retrieved on: 
Monday, August 15, 2022
Pharmaceutical, Health, Optical, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, Duane syndrome, NDA, Industry, Forward-looking statement, Food, Aerie Pharmaceuticals, Private Securities Litigation Reform Act, SEC, DME, Ocular hypertension, Security (finance), Netarsudil, Eye, Patient, COVID-19, Company, Diabetic retinopathy, Nature, NASDAQ, Coronavirus, Conjunctivitis, Glaucoma, Medication, Employment, Aerie, IOP, New Drug Application, Retina, Pharmaceutical industry

In clinical trials of Rhopressa, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage.

Key Points: 
  • In clinical trials of Rhopressa, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage.
  • In clinical trials of Rocklatan, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage.
  • More information on Aerie Pharmaceuticals is available at www.aeriepharma.com .
  • Any forward-looking statements that we make in this press release speak only as of the date of this press release.

Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Disease

Retrieved on: 
Monday, August 1, 2022
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, Aerie Pharmaceuticals, Time, Medication, Eye, DME, Food and Drug Administration, Industry, Food, Ocular hypertension, Glaucoma, Medicine, U.S. Securities and Exchange Commission, Dry eye syndrome, SEC, Forward-looking statement, Conjunctivitis, Private Securities Litigation Reform Act, NDA, DED, Duane syndrome, COMET, TRPM8, Safety, NASDAQ, Quality of life, Medical Affairs Bureau, IOP, FDA, Security (finance), Patient, Cornea, Diabetic retinopathy, Netarsudil, Sensation, Eyelid, Aerie, Pharmaceutical industry

Aerie plans to initiate the last of the trials, the COMET-4 safety study, in the fourth quarter of 2022.

Key Points: 
  • Aerie plans to initiate the last of the trials, the COMET-4 safety study, in the fourth quarter of 2022.
  • Study participants will be randomized in a 1:1 ratio to receive either AR-15512 (0.003%) or AR-15512 vehicle as a drop dosed twice daily in each eye for three months.
  • Participants will be evaluated on multiple efficacy and safety assessments at multiple timepoints throughout the study.
  • Aerie is delighted to have enrolled the first participant in the COMET-3 study, said Michelle Senchyna, Ph.D., Head of Clinical Development and Medical Affairs at Aerie.

Aerie Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022 at 5:00 p.m. ET

Retrieved on: 
Thursday, July 28, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Aerie Pharmaceuticals, Health care, DME, MHRA, Food and Drug Administration, Industry, Food, Ocular hypertension, Glaucoma, Securities and Exchange Commission (Philippines), Medication, Forward-looking statement, SEC, Conjunctivitis, EMA, Private Securities Litigation Reform Act, Eye, NDA, Duane syndrome, New Drug Application, Nature, IOP, FDA, Security (finance), Patient, Medicines and Healthcare products Regulatory Agency, Diabetic retinopathy, European Medicines Agency, Netarsudil, Pharmaceutical industry, Aerie

Aeries product portfolio includes two U.S. Food and Drug Administration (FDA) approved products and a pipeline of three product candidates in clinical development.

Key Points: 
  • Aeries product portfolio includes two U.S. Food and Drug Administration (FDA) approved products and a pipeline of three product candidates in clinical development.
  • In clinical trials of Rocklatan, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage.
  • In clinical trials of Rhopressa, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage.
  • Any forward-looking statements that we make in this press release speak only as of the date of this press release.

Aerie Pharmaceuticals Announces New Employee Inducement Grant

Retrieved on: 
Friday, July 8, 2022
FDA, Pharmaceutical, Optical, Health, FDA, Patient, DME, Retina, Conjunctivitis, Duane syndrome, COVID-19, Company, Industry, Aerie Pharmaceuticals, U.S. Securities and Exchange Commission, Forward-looking statement, Netarsudil, Employment, Coronavirus, Aerie, Glaucoma, Food, Private Securities Litigation Reform Act, Ocular hypertension, IOP, Eye, SEC, New Drug Application, NASDAQ, Medication, Diabetic retinopathy, Nature, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, Security (finance), Pharmaceutical industry

In clinical trials of Rhopressa, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage.

Key Points: 
  • In clinical trials of Rhopressa, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage.
  • In clinical trials of Rocklatan, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage.
  • More information on Aerie Pharmaceuticals is available at www.aeriepharma.com .
  • Any forward-looking statements that we make in this press release speak only as of the date of this press release.

Aerie Pharmaceuticals to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET

Retrieved on: 
Wednesday, May 25, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Optical, Regulation of tobacco by the U.S. Food and Drug Administration, Private Securities Litigation Reform Act, Food, U.S. Securities and Exchange Commission, Patient, Conjunctivitis, Nature, FDA, IOP, Industry, Duane syndrome, Netarsudil, Forward-looking statement, Ocular hypertension, Aerie Pharmaceuticals, Diabetic retinopathy, Glaucoma, SEC, Eye, Security (finance), DME, Pharmaceutical industry, Aerie

In clinical trials of Rhopressa, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage.

Key Points: 
  • In clinical trials of Rhopressa, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage.
  • In clinical trials of Rocklatan, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage.
  • This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
  • Any forward-looking statements that we make in this press release speak only as of the date of this press release.

Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease

Retrieved on: 
Tuesday, May 24, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Optical, Medical Affairs Bureau, Aerie, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Private Securities Litigation Reform Act, Food, TRPM8, U.S. Securities and Exchange Commission, Dry eye syndrome, New Drug Application, Patient, NASDAQ, Quality of life, DED, Conjunctivitis, Eye, Duane syndrome, FDA, IOP, Industry, Medication, Netarsudil, Forward-looking statement, Aerie Pharmaceuticals, Ocular hypertension, Safety, Eyelid, NDA, Sensation, Diabetic retinopathy, Glaucoma, SEC, Cornea, Security (finance), DME, Pharmaceutical industry, Medical imaging

COMET-2 is the first of three trials in the Phase 3 registrational program for AR-15512.

Key Points: 
  • COMET-2 is the first of three trials in the Phase 3 registrational program for AR-15512.
  • Study participants will receive AR-15512 (0.003%) or AR-15512 vehicle as a drop dosed twice daily in each eye for three months.
  • Participants will be evaluated on multiple efficacy and safety assessments at multiple timepoints throughout the study.
  • AR-15512 has the potential to be the new standard of care for patients suffering from dry eye disease.

Aerie Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 5, 2022
Pharmaceutical, Optical, Health, Other Health, U.S. Securities and Exchange Commission, Forward-looking statement, Investment, Mission statement, Table, Private Securities Litigation Reform Act, GAAP, Aerie Pharmaceuticals, EMA, IOP, Health care, NASDAQ, MHRA, DME, Nature, NDA, Software, Food, Ocular hypertension, Patient, Security (finance), Medication, Eye, Webcast, Diabetic retinopathy, FDA, Industry, Regulation of tobacco by the U.S. Food and Drug Administration, European Medicines Agency, New Drug Application, Medicines and Healthcare products Regulatory Agency, Aerie, Conjunctivitis, Glaucoma, SEC, ID, Duane syndrome, Growth, Netarsudil, Pharmaceutical industry, Bank, Risk management, House of Santen

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today reports financial results for the first quarter ended March 31, 2022 and reaffirms the business and pipeline objectives and financial guidance previously reported for 2022.

Key Points: 
  • Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today reports financial results for the first quarter ended March 31, 2022 and reaffirms the business and pipeline objectives and financial guidance previously reported for 2022.
  • During the first quarter of 2022, our net cash provided by operating activities was $61.9 million.
  • Further, an $8.0 million milestone payment was made in the first quarter of 2022 to the former shareholders of Avizorex Pharma S.L., which was acquired by Aerie in 2019.
  • Investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool.

Aerie Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022 at 5:00 p.m. ET

Retrieved on: 
Thursday, April 28, 2022
Pharmaceutical, Optical, Health, Other Health, U.S. Securities and Exchange Commission, Eye, Patient, FDA, DME, Private Securities Litigation Reform Act, Food, Duane syndrome, Forward-looking statement, Glaucoma, Aerie Pharmaceuticals, Security (finance), Netarsudil, Diabetic retinopathy, Nature, Industry, SEC, IOP, Regulation of tobacco by the U.S. Food and Drug Administration, Ocular hypertension, Conjunctivitis, Pharmaceutical industry, Aerie

In clinical trials of Rhopressa, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage.

Key Points: 
  • In clinical trials of Rhopressa, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage.
  • In clinical trials of Rocklatan, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage.
  • This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
  • Any forward-looking statements that we make in this press release speak only as of the date of this press release.